It’s Not Too Late to Register for eRACE Lung Cancer®
|
|
Walkers, runners, swimmers, and cyclists have joined eRACE Lung Cancer® this May, raising over $100,000 and counting! There’s still time to join participants from across the country in this month-long activity challenge to work toward one common goal: to erase lung cancer. |
Register to track your activity through May 31, then tune in to the virtual wrap-up celebration on June 2 at 7 pm EST via Zoom.
New EGFR Patient Gateway Launched
|
|
The latest in a series of targeted resources for people with lung cancer, LUNGevity’s new EGFR Patient Gateway provides patients with EGFR-positive lung cancer and their caregivers a central online hub for information, scientific news, and webinars that are specific to their cancer subtype. The Gateway also helps you find supportive communities of fellow survivors and caregivers. |
This newest resource joins Gateways for KRAS, ALK, and non-small cell lung cancer (NSCLC). Other Gateways coming soon include small cell lung cancer (SCLC), and other rare mutations and fusions (ROS1, MET, NTRK, BRAF, and RET).
More Patient Gateway Highlights
The EGFR Patient Gateway joins the ALK, KRAS, and NSCLC platforms at gateway.lungevity.org. Be sure to check back frequently for the latest expert webinars, videos, and blogs, including:
You Can Help! Paid Research Study on Mobile Technology in Lung Cancer Clinical Trials
If you have been diagnosed with non-small cell lung cancer (NSCLC), you may be able to guide the use of mobile health technology in future clinical trials. If you are interested, we welcome your participation in a new study called Lung Cancer in Motion. You can participate from the comfort of your home! Participants will be compensated for their time.
For more information on how to get involved, please contact Marie Ortloff at L&E Research: (877) 617-8662 or recruitment@leresearch.com.
LUNGevity Collaborates with ACCC on Study of HCPs and Biomarker Testing in NSCLC
|
|
LUNGevity’s Nikki Martin, MA, Senior Director of Precision Medicine Initiatives, and Upal Basu Roy, PhD, MPH, Executive Director of Research, collaborated with several other leaders from the Association of Community Cancer Centers (ACCC) on a study published in the latest issue of the ACCC journal Oncology Issues. The article summarizes results from a study analyzing how different factors influence healthcare providers’ decisions to order biomarker testing for their patients with lung cancer. |
Upcoming Webinars
Be sure to check our events calendar for the latest information on expert speaker webinars like these:
May 18 - Amy Moore, PhD, on Navigating Our New Normal: Living with COVID-19 (in partnership with Lung Health Foundation of Canada)
May 26 – Conversations That Count Series, moderated by Eugene Manley, Jr., PhD: A Panel on Asian Women and Lung Cancer Screening Disparities
Panelists include:
- Jeff Velotta, MD | Associate Thoracic Surgeon, Kaiser Permanente Northern California Oakland Medical Center Assistant Clinical Professor, UCSF School of Medicine, Department of Surgery
- Kristi Chan | Survivor and mother
- Scarlett Gomez, PhD, MPH | Professor & Vice Chair for Faculty Development, Department of Epidemiology and Biostatistics; and Co-Leader, Cancer Control Program, Helen Diller Family Comprehensive Cancer Center Director, Greater Bay Area Cancer Registry
- Iona Cheng, PhD, MPH | Professor, Department of Epidemiology and Biostatistics, Cancer Control Program, Helen Diller Family Comprehensive Cancer Center
